South Korea · Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 200.68 billion. The enterprise value is 240.76 billion.
| Market Cap | 200.68B |
| Enterprise Value | 240.76B |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 9.09% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 7.02.
| PE Ratio | 7.02 |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 7.17 |
| P/OCF Ratio | 4.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.68, with an EV/FCF ratio of 8.60.
| EV / Earnings | 8.42 |
| EV / Sales | 0.93 |
| EV / EBITDA | 4.68 |
| EV / EBIT | 7.24 |
| EV / FCF | 8.60 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.05 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 0.98 |
| Debt / FCF | 1.81 |
| Interest Coverage | 11.72 |
Financial Efficiency
Return on equity (ROE) is 13.59% and return on invested capital (ROIC) is 12.02%.
| Return on Equity (ROE) | 13.59% |
| Return on Assets (ROA) | 6.46% |
| Return on Invested Capital (ROIC) | 12.02% |
| Return on Capital Employed (ROCE) | 14.22% |
| Weighted Average Cost of Capital (WACC) | 5.86% |
| Revenue Per Employee | 868.11M |
| Profits Per Employee | 96.32M |
| Employee Count | 297 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 5.53 |
Taxes
In the past 12 months, JW Lifescience has paid 3.14 billion in taxes.
| Income Tax | 3.14B |
| Effective Tax Rate | 9.89% |
Stock Price Statistics
The stock price has increased by +15.20% in the last 52 weeks. The beta is 0.33, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +15.20% |
| 50-Day Moving Average | 13,011.80 |
| 200-Day Moving Average | 12,937.05 |
| Relative Strength Index (RSI) | 53.11 |
| Average Volume (20 Days) | 34,096 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 257.83 billion and earned 28.61 billion in profits. Earnings per share was 1,847.00.
| Revenue | 257.83B |
| Gross Profit | 72.25B |
| Operating Income | 33.24B |
| Pretax Income | 31.75B |
| Net Income | 28.61B |
| EBITDA | 51.44B |
| EBIT | 33.24B |
| Earnings Per Share (EPS) | 1,847.00 |
Balance Sheet
The company has 10.49 billion in cash and 50.57 billion in debt, with a net cash position of -40.08 billion or -2,588.63 per share.
| Cash & Cash Equivalents | 10.49B |
| Total Debt | 50.57B |
| Net Cash | -40.08B |
| Net Cash Per Share | -2,588.63 |
| Equity (Book Value) | 220.58B |
| Book Value Per Share | 14,233.31 |
| Working Capital | 3.86B |
Cash Flow
In the last 12 months, operating cash flow was 40.54 billion and capital expenditures -12.55 billion, giving a free cash flow of 27.98 billion.
| Operating Cash Flow | 40.54B |
| Capital Expenditures | -12.55B |
| Depreciation & Amortization | 18.19B |
| Net Borrowing | -18.56B |
| Free Cash Flow | 27.98B |
| FCF Per Share | 1,807.14 |
Margins
Gross margin is 28.02%, with operating and profit margins of 12.89% and 11.09%.
| Gross Margin | 28.02% |
| Operating Margin | 12.89% |
| Pretax Margin | 12.31% |
| Profit Margin | 11.09% |
| EBITDA Margin | 19.95% |
| EBIT Margin | 12.89% |
| FCF Margin | 10.85% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 3.89%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 3.89% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.07% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 3.88% |
| Earnings Yield | 14.25% |
| FCF Yield | 13.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 3 and a Piotroski F-Score of 6.
| Altman Z-Score | 3 |
| Piotroski F-Score | 6 |